Physician profile
Dorothy Wang
NPI 1497942353
$25,069.53
in general payments reported to CMS, 2019-2025
22 companies · $564 in 2025
The $564 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $847 · 2021: $78.52 · 2022: $5,864 · 2023: $16K · 2024: $1,219 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $9,600 · Consulting Fee: $6,600 · Food and Beverage: $1,505 · Travel and Lodging: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $9,600.00 |
| Consulting Fee | $6,600.00 |
| Food and Beverage | $1,505.09 |
| Travel and Lodging | $191.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $22,141.18 | 2020-2024 | |
| C. R. Bard, INC. & Subsidiaries | $500.00 | 2022 | |
| Stryker Corporation | $429.85 | 2019-2024 | Xpress Ent Dilation System, Xpress Loprofile |
| Regeneron Healthcare Solutions, INC. | $252.21 | 2022-2025 | Dupixent |
| Glaxosmithkline, LLC. | $225.03 | 2023-2025 | Nucala |
| Medtronic, INC. | $205.35 | 2024-2025 | Signia, Propel |
| Acclarent, INC | $178.20 | 2019-2023 | Trudi Nav Cable |
| Integra Lifesciences Corporation | $157.35 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Abbvie INC. | $152.57 | 2023 | Botox |
| Regeneron Pharmaceuticals, INC. | $128.58 | 2025 | Libtayo |
| Neurent Medical Limited | $126.08 | 2022-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Novo Nordisk INC | $124.02 | 2023 | |
| Optinose US, INC. | $75.82 | 2019-2025 | |
| Gilead Sciences, INC. | $74.29 | 2024 | Trodelvy |
| Aerin Medical INC. | $61.87 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $56.34 | 2019 | |
| Genzyme Corporation | $44.96 | 2024 | |
| Smith+Nephew, INC. | $38.76 | 2019-2024 | Rf20000, Coblation, Tula |
| Hikma Pharmaceuticals USA | $37.17 | 2022-2023 | Ryaltris |
| Merz North America, INC. | $25.95 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $21.95 | 2025 | Tezspire |
| Karl Storz Endoscopy-America | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorothy Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.